120568-18-5

Basic information

• Product Name: 2-Butyl-4-chloro-1-[[2'-[1-(triphenylmethyl)-1H-tetrazol-5-yl][1,1'-biphenyl]-4-yl]methyl]-1H-imidazole-5-carboxaldehyde
• Synonyms: 2-Butyl-4-chloro-1-[[2'-[1-(triphenylmethyl)-1H-tetrazol-5-yl][1,1'-biphenyl]-4-yl]methyl]-1H-imidazole-5-carboxaldehyde;N-Trityl Losartan Carboxaldehyde;2-Butyl-4-chloro-1-[[2'-[1-(triphenylMethyl)-1H-tetrazol-5-yl][1,1'-biphenyl]-4-yl]Methyl]-;N-Trityl Losartan-d4 Carboxaldehyde
• CAS NO: 120568-18-5
• Molecular Formula: C₄₁H₃₅ClN₆O
• Molecular Weight: 663.21
• Product Categories: Aromatics;Heterocycles;Intermediates
• Mol File: 120568-18-5.mol

Chemical Properties

• Appearance: /
• Storage Temp.: Refrigerator
• Solubility: Chloroform, Dichloromethane, Dimethyl Formamide, Ethyl Acetate, MEthanol
• CAS DataBase Reference: 2-Butyl-4-chloro-1-[[2'-[1-(triphenylmethyl)-1H-tetrazol-5-yl][1,1'-biphenyl]-4-yl]methyl]-1H-imidazole-5-carboxaldehyde(CAS DataBase Reference)
• NIST Chemistry Reference: 2-Butyl-4-chloro-1-[[2'-[1-(triphenylmethyl)-1H-tetrazol-5-yl][1,1'-biphenyl]-4-yl]methyl]-1H-imidazole-5-carboxaldehyde(120568-18-5)
• EPA Substance Registry System: 2-Butyl-4-chloro-1-[[2'-[1-(triphenylmethyl)-1H-tetrazol-5-yl][1,1'-biphenyl]-4-yl]methyl]-1H-imidazole-5-carboxaldehyde(120568-18-5)

Safety Data

• Hazardous Substances Data: 120568-18-5(Hazardous Substances Data)

Usage

Uses

1. Used in Pharmaceutical Synthesis:
2-Butyl-4-chloro-1-[[2'-[1-(triphenylmethyl)-1H-tetrazol-5-yl][1,1'-biphenyl]-4-yl]methyl]-1H-imidazole-5-carboxaldehyde is used as an intermediate in the synthesis of EXP 3174, a metabolite of Losartan. Losartan is an angiotensin II receptor blocker (ARB) used to treat hypertension and heart failure. The compound plays a crucial role in the development of new pharmaceuticals by facilitating the production of Losartan's active metabolite.
2. Used in Radiolabeled Compounds:
As a labelled intermediate, 2-Butyl-4-chloro-1-[[2'-[1-(triphenylmethyl)-1H-tetrazol-5-yl][1,1'-biphenyl]-4-yl]methyl]-1H-imidazole-5-carboxaldehyde is utilized in the synthesis of radiolabeled EXP 3174. Radiolabeled compounds are essential in various fields, including medical imaging, drug development, and research. The radiolabeling of EXP 3174 can help in understanding the pharmacokinetics, biodistribution, and mechanism of action of Losartan and its metabolites, contributing to the advancement of therapeutic strategies for hypertension and heart failure.
3. Used in Chemical Research:
Given its unique structural features, 2-Butyl-4-chloro-1-[[2'-[1-(triphenylmethyl)-1H-tetrazol-5-yl][1,1'-biphenyl]-4-yl]methyl]-1H-imidazole-5-carboxaldehyde may also be employed in chemical research for the development of novel compounds with potential applications in various industries, such as materials science, agrochemicals, and pharmaceuticals. Its synthesis and modification can lead to the discovery of new molecules with improved properties and functionalities.

Upstream product

• 124751-00-4 2-Butyl-4-chloro-1-[[2'-[1-(triphenylmethyl)-1H-tetrazol-5-yl][1,1'-biphenyl]-4-yl]methyl]-1H-imidazole-5-methanol 
• 83857-96-9 2-n-butyl-4-chloro-1H-imidazol-5-carboxaldehyde 
• 124750-51-2 N-(triephenylmethyl)-5-<4'-(bromomethyl)-biphenyl-2-yl>tetrazole 
• 894806-33-8 2-n-butyl-4-chloro-1-[4-(5,5-dimethyl-[1,3,2]dioxaborinan-2-yl)benzyl]-1H-imidazole-5-carbaldehyde 
• 905456-95-3 2-butyl-1-((2'-(1-trityl-1H-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)methyl)-1H-imidazole-5-carbaldehyde 
• 894806-32-7 (4-((2-butyl-4-chloro-5-formyl-1H-imidazol-1-yl)methyl)phenyl)-boronic acid 
• 143945-72-6 N-trityl-5-(2-bromophenyl)tetrazole 
• 894806-34-9 2-butyl-4-chloro-1-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzyl)-1H-imidazole-5-carbaldehyde 

Downstream Products

• 905456-95-3 2-butyl-1-((2'-(1-trityl-1H-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)methyl)-1H-imidazole-5-carbaldehyde 
• 124751-00-4 2-Butyl-4-chloro-1-[[2'-[1-(triphenylmethyl)-1H-tetrazol-5-yl][1,1'-biphenyl]-4-yl]methyl]-1H-imidazole-5-methanol 

Relevant articles and documents

Monodentate Transient Directing Group Enabled Pd-Catalyzed Ortho-C-H Methoxylation and Chlorination of Benzaldehydes

We report Pd-catalyzed ortho-C-H methoxylation and chlorination of benzaldehydes by employing monodentate transient directing groups (TDGs) as an alternative strategy to bidentate TDGs. More importantly, a single crystal of benzaldehyde imine ortho-cyclopalladium intermediate was successfully obtained, and its structure was unambiguously determined by X-ray diffraction, which clearly showed that it was a binuclear palladium species bridged by a pyridone ligand. The utility of this approach was further demonstrated through the synthesis of key intermediates of natural products and drugs.

Dual-acting antihypertensive agents

The invention is directed to compounds having the formula: wherein: Ar, r, Y, Z, Q, W, X, and R5-7 are as defined in the specification, and pharmaceutically acceptable salts thereof. These compounds have AT1 receptor antagonist activity and neprilysin inhibition activity. The invention is also directed to pharmaceutical compositions comprising such compounds; methods of using such compounds; and process and intermediates for preparing such compounds.

A PROCESS FOR PREPARATION OF 2-N-BUTYL -4-CHLORO - 1 - {[2`- (2-TRIPHENYLMETHYL - 2H - TETRAZOLE - 5- YL) - 1, 1’ - BIPHENYL-4-YL] METHYL}-LH- IMIDAZOIE-5-METHANOL (INTERMEDIATE OF LOSARTAN)

The present invention relates to a process for preparation of N-substituted heterocyclic derivative,2-n-Butyl-4-chloro- 1 - { [2' -(2-triphenylmethyl-2H-tetrazole-5-yl)- 1,1' -biphenyl -4-yl] methyl} -lH-imidazole-5-methanol, an important intermediate in the synthesis of Losartan and its pharmaceutically acceptable salts using phase transfer catalyst and minimal number of solvents with improved yield.

Angiotensin II receptor blocking agents

This disclosure describes novel imidazole compounds having the formula: STR1 wherein R 1 and R 6 are described in the specification which have activity as angiotensin II (AII) antagonists.